225 Thousand compounds in stock
Original and unique
Make-on-demand
Building Blocks

210 Million novel building blocks
Reliable supply
Over 650 highly skillful chemists
Unique synthesis technologies
14 Billion REAL compounds and
Custom Library Synthesis
On site access to all Enamine stock BB’s
Highly flexible arrangements
2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from March 2021
Recent News
05 April 2021
News
We still have several funded Postdoc positions in organic chemistry to work at Enamine Ltd. (Ukraine, Kyiv) on a ERC-project “Saturated bioisosteres of benzene.”
Start: any time.
Please, send the application documents (motivation letter, CV, list of publications, recommendation letters) to Pavel.MykhailiukATmail.enamine.net
01 March 2021
News
We are happy to announce the start of Project ALISE supported by European Commission under Horizon 2020 MSCA-RISE. As the coordinator of the Project, Enamine is involved in the development of light-controllable antibody peptide conjugates pushing the boundaries of photopharmacology towards clinical applications.
24 February 2021
Press Releases
A new multi-year drug discovery agreement will focus on CNS drug discovery
Kyiv, Ukraine, February 24 2021 - Enamine Ltd. a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments and screening compounds announced today that it has extended its long-standing research collaboration with Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company specialized in allosteric modulation-based drug discovery and development. Enamine is providing Addex with its integrated capability in medicinal chemistry, pharmacology and ADME/PK (Absorption, Distribution, Metabolism, Excretion/Pharmacokinetics) to efficiently support Addex’ small molecule CNS drug discovery programs.
Read press release
In Vivo Pharmacology and Toxicology
Enamine provides a broad range of non-GLP animal studies in toxicity, pharmacokinetics, drug efficacy and disease models in rodents.
Our services:
Our professional in vivo team has successfully completed numerous PK and toxicology studies and would be glad to design the animal study customized to your project. In addition, our animal facility is due to expand in 2018 to 5000 square feet. This will result in a substantial increase of in vivo services offered.